A neural model classifies neuroblastoma risk groups in small plasma-sample cohorts
Source check: Source checked. Not independent scientific confirmation.
Finding: A neural classifier combined exosomal enzyme measurements with clinical indicators to distinguish recorded neuroblastoma risk groups. The source used 30 pretreatment plasma specimens for development and 14 later diagnostic samples for evaluation. This is a small retrospective risk-label classification study, not a validated forecast of future outcomes or evidence that the biosensor or AI improves treatment.
Technology: Neural-network clinical/biomarker classification compared with ten other learned classifiers
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The learned neural classifier combines a measured plasma biomarker with clinical variables to estimate existing risk-group labels; AI is not credited with engineering the biosensor or the separate experimental mechanisms.
- Test and result
- A classifier combining exosomal uracil-DNA glycosylase and four clinical indicators was evaluated against recorded low/intermediate versus high-risk labels, including a later 14-sample cohort.
- Limitation / still unknown
- The initial 50 specimens include repeated samples, so they are not 50 independent patients. Model selection among 11 classifiers and small evaluation groups can inflate apparent accuracy. Some clinical inputs are themselves related to standard risk-group definitions; independent additional prognostic information and future-event prediction are not established. The separate biosensor design, biological imaging and drug-resistance experiments are outside AI attribution in this record.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13616298/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Exact primary DOI/title/PMID/date; safe clinical cohort, classifier/statistical description and high-level risk-classification Results. Biosensor construction, cell/animal procedures and sequences were not used. Same-day primary status metadata reused..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.